Phase 3 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 years or older
- People who have been diagnosed with chronic lymphocytic leukaemia (CLL), multiple myeloma (MM), or non-Hodgkin lymphoma (NHL)
- People who have been receiving immunoglobulin (Ig) therapy — given either through a drip or an injection under the skin — to prevent bacterial infections due to low antibody levels, for more than 6 months in a row
- People whose treating doctor considers it appropriate to try stopping Ig therapy as part of this trial
- People with a life expectancy of more than 12 months
- People who are able to give informed consent and are willing and able to follow the requirements of both treatment arms in the trial
Who may not be able to join:
- People who have had, or are planned to have, a stem cell transplant from a donor
- People who have had a serious infection (graded as severe or higher) in the past 3 months, or who currently have an active infection being treated with antimicrobial medication
- People who are already taking daily antibiotics specifically to prevent bacterial infections (note: preventive antiviral, antifungal, or PJP medications do not apply here)
- People who cannot tolerate any of the antibiotic options offered in either arm of the trial
- People for whom communication difficulties, compliance challenges, or practical barriers are likely to make it hard to take antibiotics as directed or to seek urgent medical attention if signs of infection develop
- People who are pregnant or breastfeeding
- People with severely reduced kidney function (creatinine clearance below 30 mL/min)
- People who have had their spleen removed
- People who have previously taken part in this trial
- People whose treating medical team considers participation in the trial to not be in their best interests
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Prof Erica Wood, Monash University
Phone: +61 3 9903 0379
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Event-free survival (EFS), defined as time from randomisation until occurrence of a Grade 3 or higher infection (as defined by CTCAE Version 5), or death from any cause.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.